Clinical Trials Browser

Phase 2 × Endometrial Adenocarcinoma × nintedanib × Clear all

NCT01225887 2017-10-09

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

37 enrolled 11 charts

GenitourinaryGynecologic

Endometrial Adenocarcinoma